Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

976
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
976
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.7K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.3K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When Everything Matters: Choosing What Truly Counts in Academic Medicine.

WMJ : official publication of the State Medical Society of Wisconsin·2026
Same author

Cronkhite-Canada syndrome, hypothyroidism and positive autoantibodies: a case report.

Journal of medical case reports·2026
Same author

A Season of Gratitude: Honoring the Community That Sustains Us.

WMJ : official publication of the State Medical Society of Wisconsin·2026
Same author

CyExpDB: a web-based multi-species tissue-specific gene expression platform for functional genomics in Cyprinidae fish.

Database : the journal of biological databases and curation·2025
Same author

The Power of Mindfulness in Medicine.

WMJ : official publication of the State Medical Society of Wisconsin·2025
Same author

Cultivating the Next Generation of Physician-Scholars.

WMJ : official publication of the State Medical Society of Wisconsin·2025

Related Experiment Video

Updated: Feb 12, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

701

Lupus Nephritis: A Treatment Update.

Fahad Aziz1, Kunal Chaudhary2,3

  • 1Division of Nephrology, University of Wisconsin, Madison, WI 53706, United States.

Current Clinical Pharmacology
|April 4, 2018
PubMed
Summary

Early diagnosis and tailored treatment of lupus nephritis (LN) are crucial for better renal outcomes. This review explores current and future pharmacological options for all LN classes, addressing treatment challenges and individualizing care.

Keywords:
Lupus nephritisclasses of lupus nephritisinduction therapymaintenance therapyresistant lupus nephritis.

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.7K
Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method
05:28

Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method

Published on: May 2, 2022

2.6K

Related Experiment Videos

Last Updated: Feb 12, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

701
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.7K
Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method
05:28

Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method

Published on: May 2, 2022

2.6K

Area of Science:

  • Nephrology
  • Immunology
  • Rheumatology

Background:

  • Lupus nephritis (LN) is a frequent complication of systemic lupus erythematosus, impacting renal health.
  • Early diagnosis and effective treatment are vital for improving patient renal outcomes.
  • Renal-limited lupus nephritis is also a recognized clinical entity.

Purpose of the Study:

  • To review current pharmacological treatments for all six classes of lupus nephritis (LN).
  • To explore strategies for managing treatment resistance, side effects, and relapses in LN.
  • To discuss future therapeutic options for lupus nephritis.

Main Methods:

  • Comprehensive literature review of available treatment guidelines for lupus nephritis.
  • Detailed analysis of pharmacological interventions across different LN histological classes.
  • Synthesis of data on managing refractory cases and treatment-related complications.

Main Results:

  • Treatment for lupus nephritis is guided by histological classification, with Classes I-II generally not requiring specific therapy.
  • Classes III and IV necessitate immunosuppressive treatment, while Classes V and VI management remains debated.
  • Multiple guidelines exist, offering varied approaches to LN management.

Conclusions:

  • Individualized treatment based on risk-benefit profiles is essential for lupus nephritis management.
  • Therapeutic approaches for induction and maintenance immunosuppression are available for different LN classes.
  • Poor response to initial lupus nephritis treatment correlates with adverse renal outcomes.